Ultragenyx Pharmaceutical Inc at JPMorgan Healthcare Conference (Virtual) Transcript
All right. Good afternoon, everyone, from the virtual JPMorgan Healthcare Conference. My name is Cory Kasimov. I'm senior large-cap biotech analyst. And it's my pleasure to introduce our next company, Ultragenyx Pharmaceutical and CEO, Emil Kakkis.
Please note that following this presentation, we will have a Q&A session where you have the ability to submit questions via the little blue button in your conference portal. So with that, Emil, thank you for being here today, and let me turn things over to you.
Thanks, Cory. Thanks for having me today, and welcome, everyone. Ultragenyx, if you're on the first slide, I'd move on to your second slide is the legal warning. And let's move on to the next. The companies now after 10 years, been building really an exceptional rare disease company from the standpoint of building a commercial enterprise with the Crysvita, Dojolvi launch
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |